drugset / Trial / NCT02468687
NMP in Relapsed / Refractory Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate if the N-methyl-pyrrolidone (NMP) can be safely administered to humans at doses, which induce measurable immunological and anti-tumour effects in patients with myeloma who are resistant to or intolerant of lenalidomide and bortezomib.
Timeline
- Start
- 2015-08-20
- Primary completion
- 2021-10-07
- Completion
- 2021-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | METHYLPYRROLIDONE | Small molecule | 50 mg | Oral |